Faster and safer safety cabinet fumigation

Published: 18-Feb-2011
Containment Manufacturing Ingredients Regulatory Cleaning

Hydrogen peroxide system offers alternative to toxic formaldehyde fumigation of safety cabinets

New from isolator producer Skan AG is the Skanair DECOSIS fumigation system, which eliminates biosafety risks prior to the maintenance of microbiological safety cabinets and other biocontainment units.

An easier and faster alternative to formaldehyde fumigation, the Skanair DECOSIS is a mobile unit used directly in the lab, and connected to the safety cabinet via two tubes. It functions autonomously thanks to a control system and catalytic converter.

Because it uses hydrogen peroxide (H2O2) as a biocide, decomposition products are unproblematic, and maintenance work can subsequently be safely carried out on the decontaminated cabinet.

The unit can be used to decontaminate microbiological safety cabinets in advance of maintenance work, when changing job or location, in preparation for disposal, or in the event of breakdowns or accidents.

It can also be used to decontaminate incubators, air locks and small isolators.

The cabinet continues to run in reduced mode throughout the procedure. The trained maintenance technician enters the corresponding facility parameters at a control system display, together with the quantity of H2O2 defined on the basis of the Skanair DECOSIS validation.

The process starts at the touch of a button, and runs completely automatically: the internal ventilation unit maintains slight negative pressure and feeds H2O2 vapour through the front cover into the cabinet, continuously circulating it inside the cabinet to reach all contaminated areas. The exhaust air through the cabinet‘s HEPA filter is then fed back into the Skanair DECOSIS via the second tube to be recirculated.

The decontamination phase is followed by the flushing phase: any biocides in the exhaust air from the cabinet are removed inside the Skanair DECOSIS via a catalytic converter and a final HEPA filter. This air can then be released directly into the lab, without having to be extracted via the building exhaust air system.

See more

You may also like

Containment

Ajinomoto Bio-Pharma Services expands fill-finish with new suite

Read more
The biopharma CDMO has announced it will soon open a high-speed multi-purpose fill-finish line in its commercial manufacturing facility located in San Diego, CA

Trending Articles

  1. Roche wins CE mark for first blood-based immunoassay to identify ApoE4 Alzheimer's risk variant Roche's Elecsys ApoE4 test has received CE mark approval as the first in-vitro diagnostic immunoassay to detect the ApoE4 genetic variant from a simple blood sample, potentially eliminating the need for confirmatory DNA testing in Alzheimer's patients who do not carry the variant
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Moving with speed and scale: innovative, material-sparing approaches to accelerate clinical development As early-stage drug development is often hindered by limited API supply, rising costs and tight timelines, material-sparing technologies are helping companies to progress faster with less
  3. Why weight sorting should move earlier in OSD development Phillip Ruda explains how earlier weight intelligence can improve process understanding, reduce risk and accelerate learning cycles
  4. Orphan drug sales to exceed $400bn by 2032, Evaluate report finds Despite FDA policy shifts and the rise of blockbuster obesity drugs, a new Evaluate report confirms rare disease therapies are on track to claim more than a fifth of all global prescription drug sales within a decade
  5. Lyocontract invests €50m in new freeze-drying facility with Syntegon vial line German CDMO Lyocontract has begun construction of a €50m expansion in Ilsenburg, partnering with Syntegon to install a complete vial filling and lyophilisation line for sterile freeze-dried pharmaceuticals

Upcoming event

DCAT Week

23–26 March 2026 | Conference | New York, US See all

You may also like

Containment

Ajinomoto Bio-Pharma Services expands fill-finish with new suite

The biopharma CDMO has announced it will soon open a high-speed multi-purpose fill-finish line in its commercial manufacturing facility located in San Diego, CA
Manufacturing

Abzena named a leader in Frost & Sullivan ADC CDMO radar report

Recognition highlights integrated capabilities, proprietary technology and expertise in antibody-drug conjugates
Manufacturing

LabVantage Solutions introduces LabVantage CORTEX, advancing its LIMS platform for AI-driven laboratory operations

Next-Generation Platform Extends LIMS with Agentic AI and Cloud-Native Automation to Improve Efficiency, Reduce Errors and Gain Deeper Insight from Data. Learn More from LabVantage Leadership at Pittcon 2026
Design & Build

Entries closed: what’s next for the Cleanroom Technology Awards?

With entries now closed, attention turns to the next phase of the awards programme
Manufacturing

Schütz to build automated IBC production facility at BASF's Ludwigshafen headquarters

Packaging specialist Schütz has signed an agreement with BASF to construct a highly automated intermediate bulk container manufacturing and storage facility directly adjacent to the chemical giant's main plant in Ludwigshafen, enabling round-the-clock just-in-time delivery
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities

The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
Manufacturing

SGD Pharma partners with Prince Sterilisation Services for pharmaceutical glass packaging

The pair have already launched the My Sterinity Nasal platform, a new, versatile sterile vial range within SGD Pharma's My Sterinity RTU platform, using the company's U-Save Type I vials, which are designed to support the growing segment of high-value nasal drug delivery
Subscribe now